Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Results for current Phase-III study of Ketotransdel is expected in the third quarter of 2009
Subscribe to our email newsletter
California-based pharmaceutical company, Transdel has announced that it anticipate reporting top-line results from its current phase-III study of Ketotransdel during the third quarter of 2009.
The phase-III study consists of a randomized, double-blind, placebo controlled trial to evaluate the efficacy and safety of Ketotransdel, a topical cream based non-steroidal anti-inflammatory drug (NSAID). It is used in acute soft tissue injuries of the upper and lower extremities.
After the FDA approves Ketotransdel for treatment of acute pain, the company intends to pursue FDA approval of Ketotransdel for other indications, such as osteoarthritis.
The company is in discussions with US and foreign-based potential partners with sales and marketing infrastructures to support Ketotransdel in the event that the product is approved and commercialized.